Member access

4-Traders Homepage  >  Shares  >  London Stock Exchange  >  GlaxoSmithKline plc    GSK   GB0009252882

GLAXOSMITHKLINE PLC (GSK)

173
Delayed Quote. Delayed London Stock Exchange - 01/30 11:35:00 am
1467 GBp   -1.71%
01/30DJGlaxoSmithKline plc 4Q 2014 -- Forecast
01/30 Three months on, fruitless CEO search overshadows Sanofi
01/28DJEU Approves Three-Part Deal Between Novartis, GlaxoSmithKline
SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Income Statement Evolution
Annual Income Statement Data
Actuals in M GBP Estimates in M GBP
Fiscal Period December 201120122013201420152016
Sales27 38726 43126 50523 12424 65825 410
Operating income (EBITDA)10 2319 4158 8837 6757 9338 297
Operating profit (EBIT)8 5548 3308 0156 3916 4166 737
Pre-Tax Profit (EBT)7 6986 6926 6474 6024 8885 364
Net income5 2614 5655 6283 4623 5734 002
EPS (PNC)10391,511173,581,276,4
Dividend per Share (PNC)70,074,078,080,180,881,1
Yield4,77%5,04%5,32%5,46%5,51%5,53%
Announcement Date02/07/2012
12:00pm
02/06/2013
12:01pm
02/05/2014
12:00pm
---
Finances - Leverage
Actuals in M GBP Estimates in M GBP
Fiscal Period December 201120122013201420152016
Debt9 00314 03712 64512 92811 53111 567
Finance------
Operating income (EBITDA)10 2319 4158 8837 6757 9338 297
Leverage
(Debt/EBITDA)
0,88x1,49x1,42x1,68x1,45x1,39x
Capital Expenditure9231 0511 1881 4481 4801 473
Book Value Per Share (BVPS)162 PNC120 PNC146 PNC132 PNC129 PNC115 PNC
Cash Flow per Share124 PNC87,7 PNC149 PNC102 PNC108 PNC131 PNC
Announcement Date02/07/2012
12:00pm
02/06/2013
12:01pm
02/05/2014
12:00pm
---
Balance Sheet Analysis
Assessed data source :
© 2015 Thomson Reuters
Advertisement
Financial Ratios

Size 2014e 2015e
Capitalization 71 352 M GBP -
Entreprise Value (EV) 84 280 M GBP 82 883 M GBP
Valuation 2014e 2015e
PER (Price / EPS) 20,0x 18,1x
Capitalization / Revenue 3,09x 2,89x
EV / Revenue 3,64x 3,36x
EV / EBITDA 11,0x 10,4x
Yield (DPS / Price) 5,46% 5,51%
Price to book (Price / BVPS) 11,1x 11,4x
Profitability 2014e 2015e
Operating Margin (EBIT / Sales) 27,6% 26,0%
operating Leverage (Delta EBIT / Delta Sales) -1,59x 0,06x
Net Margin (Net Profit / Revenue) 15,0% 14,5%
ROA (Net Profit / Asset) 8,80% 8,47%
ROE (Net Profit / Equities) 61,4% 69,5%
Rate of Dividend 109% 99,5%
Balance Sheet Analysis 2014e 2015e
CAPEX / Sales   6,26% 6,00%
Cash Flow / Sales (Taux d'autofinancement) 21,4% 21,3%
Capital Intensity (Assets / Sales) 1,70x 1,71x
Financial Leverage (Net Debt / EBITDA) 1,68x 1,45x
Price Earning Ratio
EPS & Dividend
Dynamic quotes  
ON
| OFF